In the context of BCC, the immunological landscape involves key co-inhibitory ICPs, such as PD-1 and its ligand, PD-L1, as well as CTLA-4, which negatively regulate T-cell activity. The gene discussed is CD274; the disease is skin basal cell carcinoma.